Prevalence of Parkinson's disease: a population‐based study in Portugal

Abstract

The results of this study show that a geographical region with a high frequency of a causal mutation for PD does not automatically imply a high prevalence of patients with PD.

The increasing prevalence of Parkinson's disease in Estonia

“…[13][14][15] The existing body of research on PD epidemiology suggests that disease frequency peaks in the age-group 80-89 years old and then declines; 5,16,17 other studies have found the highest agespecific prevalence rates among the oldest groups studied. 3,7,11,14,15,[17][18][19] Several other studies did not observe a statistically significant difference between gender and adjusted PD prevalence rates. Males have been related to higher age-adjusted prevalence rates in many studies; in only a few studies did females have higher rates.…”

“…Males have been related to higher age-adjusted prevalence rates in many studies; in only a few studies did females have higher rates. 3,7,11,14,15,[17][18][19] Several other studies did not observe a statistically significant difference between gender and adjusted PD prevalence rates. 4,6,20 Results on the role of urban or rural living on prevalence of PD are controversial.…”

“…[3][4][5][6][7][8][9][10] In door-to-door studies where patients older than 45 or 50 years old were screened, the age-adjusted rates range from 240 to 413/100 000. 11,12 Studies with an approach to case ascertainment based on the drug prescription archive or healthcare insurance databases but no clinical examination of participants, have shown the most wide-ranging age-adjusted prevalence rates, that is, 85-410/100 000 in surveys where all ages Objectives: A previous epidemiological study of Parkinson's disease (PD) in the county of Tartu, Estonia, found an adjusted prevalence rate of 152/100 000 persons.We aimed to determine PD prevalence almost 20 years later, as well as evaluate any dynamic changes in disease frequency compared to the first study. Methods: A cross-sectional, community-based study was conducted over 2010-2016 in the county of Tartu, Estonia.…”

Parkinson’s Disease and Fabry Disease: Clinical, Biochemical and Neuroimaging Analysis of Three Pedigrees

“…To the best of our knowledge, this is the first study surveying PD in a large cohort of FD patients with the p.F113L mutation. We found a higher prevalence of PD in FD patients (1.3% in the total cohort of adult FD patients and 3.0% in the subgroup of FD patients aged ≥50 years), when compared to the 0.24% adjusted prevalence of PD in community-dwelling Portuguese population, aged ≥50 years [23]. With respect to previous reports, we have found at least two common similarities, which can be highlighted as characteristic of FD with PD: higher burden of cardiac and cerebrovascular lesioning.…”

Progress in neurology 2017–2018

“…The world‐wide prevalence of Parkinson disease (PD) is rising steadily as the global population ages and significant advances are being made in the understanding of pathogenesis and treatment . It is of interest that in Portugal, where there is a high prevalence of LRRK2 G2019S mutation in PD, a recent study found PD prevalence to be 0.24% of those aged >50 years, with a total of 180/100 000 population, rather lower than might be expected, although this is probably explained by methodological issues . This mutation may be associated with specific inflammatory markers that appear to be associated with the severity of motor and non‐motor dysfunction, and these could provide a useful biomarker for stratification .…”